The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
“We are fortunate to welcome these accomplished and highly respected researchers to the Bright Minds team at this exciting juncture. As we advance our clinical programs through the regulatory ...
Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on Bright Minds Biosciences (DRUG – Research Report) today and set a price target of $93.00. The company’s shares ...
The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
"We are fortunate to welcome these accomplished and highly respected researchers to the Bright Minds team at this exciting juncture. As we advance our clinical programs through the regulatory process, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback